Entrada Therapeutics (NASDAQ:TRDA) & Oncobiologics (NASDAQ:OTLK) Head to Head Contrast

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) and Oncobiologics (NASDAQ:OTLK – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Entrada Therapeutics and Oncobiologics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Entrada Therapeutics -4,057.98% -64.00% -50.49%
Oncobiologics N/A N/A -254.82%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Entrada Therapeutics and Oncobiologics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entrada Therapeutics 1 2 4 0 2.43
Oncobiologics 1 2 2 0 2.20

Entrada Therapeutics presently has a consensus target price of $17.75, suggesting a potential upside of 255.00%. Oncobiologics has a consensus target price of $5.20, suggesting a potential upside of 1,213.13%. Given Oncobiologics’ higher possible upside, analysts plainly believe Oncobiologics is more favorable than Entrada Therapeutics.

Volatility and Risk

Entrada Therapeutics has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.

Institutional & Insider Ownership

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Entrada Therapeutics and Oncobiologics”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entrada Therapeutics $25.42 million 7.70 -$143.75 million ($3.84) -1.30
Oncobiologics $1.35 million 71.41 -$62.42 million ($0.77) -0.51

Oncobiologics has lower revenue, but higher earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Summary

Oncobiologics beats Entrada Therapeutics on 7 of the 13 factors compared between the two stocks.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.

About Oncobiologics

(Get Free Report)

Oncobiologics, Inc. changed its name to Outlook Therapeutics, Inc. in 2018 and trades under the symbol OTLK. The biotechnology company focuses on developing and commercializing treatments for eye diseases. Its lead product, Lytenava (bevacizumab gamma), is an ophthalmic formulation of bevacizumab developed to treat neovascular age-related macular degeneration, also known as wet AMD. The company has pursued regulatory approvals and commercialization of the treatment in the United States and Europe.

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.